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that eradication of H. pylori after endoscopic resection (ER) of early gastric cancer (EGC) helped prevent the development of metachronous gastric cancer. 3, 4 However, Choi et al. 5 revealed that H. pylori eradication after ER of EGC did not reduce the incidence of metachronous gastric cancer. Therefore, the importance of H. pylori eradication after ER for gastric neoplasms remains controversial. Defining the subgroup of patients for whom H. pylori eradication after ER for gastric neoplasms is beneficial is important because patients who undergo ER is increasing and the incidence of metachronous lesions is also consequently increasing.
Several gastric and intestinal epithelial markers are associated with the progression of IM, a precancerous lesion. 6, 7 Sonic hedgehog (SHH) is an essential regulator of developmental and physiological processes. [8] [9] [10] In humans, Shh mRNA and SHH protein are expressed in the normal gastric fundus but not in the esophagus and intestine. 11, 12 Loss of SHH is an early change associated with the presence of IM. 11, 13 CDX proteins (intestinespecific caudal-related homeobox transcription factor) are intestine-specific transcription factors encoded by human CDX1
and CDX2 genes. Moreover, Mizoshita et al. 14 reported that the expression of CDX1 and CDX2 was found in IM of the human stomach. Shiotani et al. 7 demonstrated the reexpression of SHH and reduction of CDX2 levels after H. pylori eradication. Sox2, a gastric transcription factor, is expressed in the human stomach, and its expression gradually decreases as IM progresses. 15 That is, Sox2 expression decreases and Cdx expression increases gradually during the progression of IM. Therefore, these markers might help identify patients for whom H. pylori eradication is advantageous. In this study, we evaluated the clinicopathological factors and gastric and intestinal markers according to the development of metachronous gastric neoplasms after ER, clarified the role of H. pylori eradication in the development of metachronous lesions, and investigated the patient subgroup for whom H. pylori eradication was beneficial, especially after ER.
Materials and Methods
Patients
Between 
Immunohistochemistry
Immunohistochemical staining was performed for SHH, CDX1, CDX2, and SOX2. Twenty patients were selected for im- 
Statistical analysis
The chi-square test and Fisher exact test were used to compare the clinicopathological factors between the groups according to the development of metachronous gastric neoplasms. The t-test was used for noncategorical variables in the intergroup comparisons of clinicopathological characteristics. The Wilcoxon signed-rank test and Mann-Whitney U-test were used for evaluating immunohistochemical expression levels. The meta- Values are presented as mean±standard deviation or number (%). *Background mucosal pathologies, such as atrophy and intestinal metaplasia, were evaluated endoscopically.
chronous and nonmetachronous groups were matched according to age and sex by using propensity score matching at a ratio of 1:3.
Statistical significance was set at P＜0.05. All statistical analyses were performed by using SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Results

Clinicopathological characteristics of the metachronous and nonmetachronous groups
Immunohistochemistry
To investigate gastric and intestinal markers according to the development of metachronous gastric neoplasms after ER, immunohistochemical staining was performed for 10 metachronous and 10 nonmetachronous patients before and after H. pylori eradication (Fig. 1) . The intensities of SOX2 staining in the antrum and SHH staining in the antrum and corpus were increased in the nonmetachronous group after H. pylori eradication (P＜ 0.05). In addition, the intensity of CDX2 staining in the antrum and corpus was decreased in the nonmetachronous group after H.
pylori eradication (P＜0.05). However, such changes in the in- tensity of SOX2, SHH, and CDX2 staining were not observed in the metachronous group. The intensity of SOX2 and SHH staining in the antrum after H. pylori eradication was significantly lower in the metachronous group than in the nonmetachronous group (P＜0.05). Moreover, the intensity of CDX2 staining in the antrum before H. pylori eradication was significantly higher in the metachronous group than in the nonmetachronous group (P＜0.05) ( Table 4) .
Discussion
The 5-year survival rate of EGC was favorable (＞95%). 18 ER is currently accepted as a local treatment for EGC, and the longterm outcome of ER for EGC in Korea is favorable. 19, 20 ER has the advantages of preserving the entire stomach and increasing the postoperative quality of life of patients; however, the risk of synchronous or metachronous gastric cancer may be higher in the remnant stomach compared with that after gastrectomy.
Metachronous gastric cancer developed in 2.7% to 14.0% of patients after ER within 3 to 5 years. 21, 22 Multiple gastric lesions are more frequent in EGC than in advanced gastric cancer. Therefore, the detection of metachronous lesions after ER is important In the present study, all patients were infected with H. pylori and received H. pylori eradication treatment. We selected such a subgroup because we wanted to identify the patients for whom H. pylori eradication treatment would be helpful. Previous studies 3, 5 reported controversial results about the effects of H.
pylori eradication treatment on metachronous gastric neoplasms.
Therefore, we selected patients who received H. pylori eradication treatment, and then investigated the clinicopathological factors that affected the development of metachronous neoplasms.
In this study, the number of patients with metachronous gastric neoplasms after ER was 34 (14 with dysplasia, 20 with carcinoma). However, the number of patients with metachronous gastric neoplasms was not small. Similar to previous studies, metachronous recurrence was observed in 33 patients during 3
years of follow-up 3 and in 27 patients during 3 years of followup. 5 Although the 3,882 patients were found to have gastric neoplasms and were scheduled for ER, the final group for the study consisted of 136 patients because we focused on those patients who received H. pylori eradication treatment. In addition, we investigated the role of H. pylori infection on the development of metachronous lesions by comparing the failure rate of H. pylori eradication; that is, we assessed the effect of persistent H.
pylori infection on metachronous lesions after ER. Open-type atrophy, severe IM, and failure of H. pylori eradication were significantly associated with metachronous gastric neoplasms.
Notably, failure of H. pylori eradication was significantly more frequent in metachronous patients with gastric dysplasia but not Values are presented as median (interquartile range). The Wilcoxon signed-rank test and Mann-Whitney U-test were used for evaluating the immunohistochemical expression levels. *P<0.05, compared between the control and metachronous groups. The expression levels were determined by scoring both the positive rate and the intensity of Sonic hedgehog (SHH), CDX1, CDX2, and SOX2 staining. The positive expression rate was determined by counting the number of immunopositive cells in three areas randomly chosen in the tissue in a total of 300 cells and given scores (0=0%, 1=1%~25%, 2=26%~35%, 3=36%~45%, 4=46%~65%, 5=66%~100%). The staining intensity was scored as follows: 0, no detectable cytoplasmic staining; 1, mild cytoplasmic staining; 2, moderate cytoplasmic staining; and 3, severe cytoplasmic staining. Two scores were then summed to obtain a final score of 0 and 8. †
The expression of SOX2 staining in the antrum increases in the control group after Helicobacter pylori eradication. ‡ The expression of SHH staining in the antrum and corpus increases in the control group after H. pylori eradication. § The expression of CDX2 staining in the antrum and corpus decreases in the control group after H. pylori eradication. However, on the basis of our results, H. pylori eradication after ER should be performed in patients with dysplasia for the prevention of metachronous lesions.
Our study has some limitations. This study was retrospective, and H. pylori eradication treatment could not be randomized.
In addition, the period between ER and H. pylori eradication varied. The background mucosa such as atrophy and IM were evaluated endoscopically, not histologically.
Bornschein et al. 26 reported that the expression levels of CDX1, CDX2, and SOX2 were similar in gastric cancer and in the surrounding nontumorous mucosa. They compared the gene expression between the tumor and the tumor-distant mucosa. In addition, upregulation of CDX1 and CDX2 and downregulation of SOX2 in the nonneoplastic gastric mucosa of patients with gastric cancer were confirmed. Moreover, H. pylori infection had no significant effect on the regulation of CDX1, CDX2, and SOX2 at the gastric cancer stage. In this study, the expression of CDX2 decreased and that of SOX2 increased after H. pylori eradication in the nonmetachronous group in which metachronous gastric neoplasm did not arise. The transgenic expression of cdx2 in the murine stomach can induce IM, which progresses to invasive gastric cancer. 27 Furthermore, SOX2 is downregulated in gastric carcinoma. 15, 28 Therefore, the negative correlation of CDX2 and inverse relation with SOX2 expression in this study might be associated with the effects of H. pylori eradication on premalignant lesions before carcinoma. SHH expression also increased after H. pylori eradication in the nonmetachronous group. Shiotani et al. 7 reported that H. pylori eradication was associated with an increase in SHH expression in the corpus, especially in the absence of incomplete IM. Incomplete IM at the corpus is more common in patients with gastric cancer, 13 which is in agreement with our finding of a positive correlation with SHH expression in the nonmetachronous group after H. pylori eradication. In summary, the expression of SHH and SOX2 increased and that of CDX2 decreased after H. pylori eradication in the nonmetachronous group in this study. Although the results were derived from a small sample size, these markers could be used to define the subgroup in which H. pylori eradication would be beneficial after ER.
In conclusion, H. pylori eradication can play an important role in the prevention of metachronous lesions after ER in patients with precancerous lesions before carcinomatous transformation. In addition, the changes in SHH, SOX2, and CDX2 expression after H. pylori eradication may be predictive markers for metachronous lesions after ER.
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